title: Wall passivation for unstable angina.
abstract: The disruption of an atherosclerotic plaque in a coronary artery, appears to be fundamental for the development of arterial thrombosis and resultant ischaemia. Platelets play a central role in the pathogenesis of unstable angina; they can aggregate and cause mechanical obstruction if large enough. In addition, they can lead to fibrin deposition and extension of the thrombus. The fundamental goal in the treatment of unstable angina is to control the acute disease process that leads to vascular occlusion. In addition to the currently available pharmacological agents used to treat unstable angina, newer agents such as the direct thrombin inhibitors and the glycoprotein IIb/IIIa receptor antagonists may be more effective in achieving 'passivation'. This article summarizes the role of the vessel wall and its interaction with platelets in arterial thrombosis. The different pharmacological approaches used in achieving passivation of platelets in unstable angina are described.
authors.affiliation: Cardiovascular Biology Research Laboratories, Mount Sinai School of Medicine, New York, NY 10029, USA.
authors.forename: M
authors.initials: M
authors.lastname: Lettino
authors.forename: F
authors.initials: F
authors.lastname: Dailey-Sterling
authors.forename: L
authors.initials: L
authors.lastname: Badimon
authors.forename: J H
authors.initials: JH
authors.lastname: Chesebro
authors.forename: J J
authors.initials: JJ
authors.lastname: Badimon
mesh_terms: D000208:Acute Disease; D000789:Angina, Unstable / Q000097:blood / Q000209:etiology / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D000991:Antithrombins / Q000008:administration & dosage / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D003324:Coronary Artery Disease / Q000097:blood / Q000150:complications / Q000628:therapy; D003328:Coronary Thrombosis / Q000097:blood / Q000150:complications / Q000628:therapy; D016503:Drug Delivery Systems; D004359:Drug Therapy, Combination; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007261:Infusions, Intra-Arterial; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011817:Rabbits; D013925:Thromboplastin / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D013925:Thromboplastin